Posted by Michael Wonder on 14 Jan 2024
Shorla Oncology announces FDA filing acceptance of new drug application for novel formulation to treat breast and ovarian cancer
9 January 2024 - Shorla Oncology announced today that the US FDA has accepted for review the company’s new drug application for a novel formulation to treat breast and ovarian cancer.
The Agency assigned a Prescription Drug User Fee Act action date of 29 June 2024.
